Marotz Clarisse A, Zarrinpar Amir
Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA.
Division of Gastroenterology, University of California, San Diego, La Jolla, CA.
Yale J Biol Med. 2016 Sep 30;89(3):383-388. eCollection 2016 Sep.
The worldwide prevalence of metabolic syndrome, which includes obesity and its associated diseases, is rising rapidly. The human gut microbiome is recognized as an independent environmental modulator of host metabolic health and disease. Research in animal models has demonstrated that the gut microbiome has the functional capacity to induce or relieve metabolic syndrome. One way to modify the human gut microbiome is by transplanting fecal matter, which contains an abundance of live microorganisms, from a healthy individual to a diseased one in the hopes of alleviating illness. Here we review recent evidence suggesting efficacy of fecal microbiota transplant (FMT) in animal models and humans for the treatment of obesity and its associated metabolic disorders.
包括肥胖及其相关疾病在内的代谢综合征在全球的患病率正在迅速上升。人类肠道微生物群被认为是宿主代谢健康和疾病的独立环境调节因子。动物模型研究表明,肠道微生物群具有诱导或缓解代谢综合征的功能能力。改变人类肠道微生物群的一种方法是将含有大量活微生物的粪便从健康个体移植到患病个体,以期缓解疾病。在此,我们综述了近期的证据,这些证据表明粪便微生物群移植(FMT)在动物模型和人类中治疗肥胖及其相关代谢紊乱方面的有效性。